Radiopharmaceuticals Forum: The Dawn of Radiopharma 2.0 and Shifting Competitive Landscape

Nuclear medicine is an independent discipline that utilizes radiation emitted by radionuclides for the diagnosis, treatment, and study of diseases, with its most distinctive features being early diagnosis and targeted therapy. In recent years, the diagnostic and therapeutic roles of radiopharmaceuticals in cardiovascular diseases, oncology, and neurodegenerative disorders have become increasingly prominent, driving substantial clinical demand. Globally, the radiopharmaceutical market is highly prosperous and is projected to reach $26 billion by 2030. In China, a multitude of new enterprises have entered the radiopharmaceutical sector, significantly advancing numerous innovative product pipelines. The initial signs of a shifting landscape in China’s radiopharmaceutical market are now emerging.

The 7th Future Healthcare Top 100 Conference, in collaboration with VCBeat New Medicine, jointly created the Radiopharmaceuticals Forum. It invited leading academic experts, industry-leading enterprises, and forward-looking investors to participate. Focusing on the future opportunities and challenges in the field of radiopharmaceuticals, the forum comprehensively explored the current development trends of the industry ecosystem from multiple perspectives.

2023 Future Healthcare Top 100 Conference, hosted by VB100, VCBeat, and Eggshell Research Institute, with strategic partnership support from Shanghai Zhangjiang Group, will be grandly held at the Shanghai Zhangjiang Science Hall from May 5–7, 2023. Led by Academician Robert Langer and IEEE scientists, nearly 500 industry luminaries will gather for three main forums and 31 hot-topic sessions!